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Abstract
Background: Ventilator-associated pneumonia (VAP) is a serious health care- associated infection, resulting in high
morbidity and mortality. It also prolongs hospital stay and drives up hospital costs. Measures employed in
preventing ventilator- associated pneumonia in developing countries are rarely reported. In this study we tried to
assess the efficacy of our designed “VAP prevention bundle” in reducing VAP rate in our neonatal intensive care
unit (NICU).
Method: This prospective before-and-after study was conducted at university hospital NICU, all neonates who had
mechanical ventilation for ≥ 48 h were eligible. VAP rates were evaluated before (phase-I) and after (phase-II) full
implementation of comprehensive preventive measures specifically designed by our infection control team.
Results: Of 143 mechanically ventilated neonates, 73 patients developed VAP (51 %) throughout the study period
(2500 mechanical ventilation days). The rate of VAP was significantly reduced from 67.8 % (42/62) corresponding to
36.4 VAP episodes/1000 mechanical ventilation days (MV days) in phase-I to 38.2 % (31/81) corresponding to 23 VAP/
1000 MV days (RR 0.565, 95 % confidence interval 0.408-0.782, p = 0.0006) after VAP prevention bundle implementation
(phase-II). Parallel significant reduction in MV days/case were documented in post-intervention period (21.50 ± 7.6 days
in phase-I versus 10.36 ± 5.2 days in phase-II, p = 0.000). There were a trend toward reduction in NICU length of stay
(23.9 ± 10.3 versus 22.8 ± 9.6 days, p = 0.56) and overall mortality (25 % versus 17.3 %, p = 0.215) between the two
phases but didn’t reach statistical significance. The commonest micro-organisms isolated throughout the study were
gram-negative bacteria (63/66, 95.5 %) particularly Klebsilla pneumonia (55/66, 83.4 %).
Conclusion: Implementation of multifaceted infection control bundle resulted in reduction of VAP rate, length of stay
in our NICU.
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Background
Ventilator-associated pneumonia (VAP) is defined by the
Center for Disease Control and Prevention (CDC) and
National Healthcare Safety Network as new and persist-
ent radiographic infiltrates and worsening gas exchange
in infants who are ventilated for at least 48 h and who
exhibit least 3 of the following criteria: temperature in-
stability with no other recognized cause, leukopenia,
change in the characteristic of respiratory secretions, re-
spiratory distress and bradycardia or tachycardia [1].
VAP is a serious complication in neonates on mechanical
ventilation and account for 6.8 - 32.2 % of health-care as-
sociated infections among neonates [2, 3]. It has a large
impact on neonatal morbidity, survival, hospital costs
and duration of neonatal intensive care unit (NICU)
stay [3, 4]. The effect of VAP on health care costs is es-
pecially significant in developing world, whereas most
studies of VAP have been conducted in developed
countries [5, 6].
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Prevention of VAP has been primarily achieved by the
“bundle approach”; this involves the simultaneous appli-
cation of several preventive strategies for all patients,
often aided by tools such as checklist. In some cases
there is only theoretical evidence or biologic plausibility
for one or more of the elements of the bundle being ef-
fective, but application of these bundles is widely used
and has been highly successful [7].
As neonates have different anatomy, physiology, under-
lying diseases and they undergo different invasive proce-
dures compared with adults and older children [8],
specific studies for evaluating different “VAP bundles” effi-
cacy in preventing VAP in NICU are needed. In Egypt and
other developing countries, reports on the success of VAP
intervention strategies, particularly among neonates, are
scarce. The aim of the present work is to assess the effect-
iveness of our proposed “VAP prevention bundle” in de-
creasing rates of neonatal VAP.
Patients and methods
Setting
The present study was conducted in the NICU of Chil-
dren Hospital of Zagazig University, Egypt from January
2013- March 2014. Our 23 bed NICU is staffed with cer-
tified physician 24 h/day, 7 days/week with a nurse-to-
patient ratio 1:3-1:4 depending on the patient acuity.
Eight mechanical ventilators and 5 nasal continuous
positive airway pressure (CPAP) are available at our unit.
A neonatologist leads daily round on all NICU patients
to review patient information and develop care plan.
Design
This before-and-after intervention prospective study
passed through the following periods; phase-I at which
VAP rate, expressed as the number of VAP episodes per
1000 mechanical ventilator days (VAP/1000 MV days)
were calculated for 6 months started at January 2013.
Throughout this period we reviewed and summarized
recommendations by different authors and health insti-
tutes regarding strategies for prevention of health care
associated infections particularly VAP. Observations
were documented by our team members regarding the
most prevalent practical errors that may contribute to
increased risk of VAP among our mechanically venti-
lated neonates. Accordingly, our “VAP preventive bun-
dle” was tailored to stress on our common errors and
include common evidence-based practices recom-
mended by previous studies and agencies [9–15].
Three months were needed (intermediate phase),
started at July 2013, until education and full implemen-
tation of the bundle by our health care providers were
satisfactory accomplished and their adherence rate
reached 86 %. During this period we performed educa-
tion session to discuss evidences about the pathogenesis,
risk factors, danger of VAP and its sequel. Training and
re-training campaigns were performed for each VAP
bundle’s item particularly hand hygiene, sterile handling
of respiratory equipment, and proper timed mouth care.
Finally, signed statement from each staff member ac-
knowledging their understanding of the policy and the
mandate to comply with it was taken, to ensure the con-
nection between policy and practice.
VAP prevention bundle
In addition to routine infection control protocol, our de-
signed bundle was composed of:
 Head-of-bed elevation 300-450.
 Re-enforcement of hand hygiene practice.
 Sterile suction and handling of respiratory
equipment.
 Intubation, re-intubation and endotracheal tube
(ETT) suction as strictly indicated by unit protocol
(document).
 Change ventilator circuit if visibly soiled or
mechanically malfunctioning (document)
 Proper timed mouth care with normal saline and
suction of oro-pharyngeal secretion.
 Daily evaluation for readiness for extubation to nasal
continuous airway pressure (NCPAP) at morning
round, and sedation vacation for sedated patient.
Written protocols were performed for strict indications
of intubation, re-intubation, suctioning of ETTand change
of the ventilator circuit. Documentation is needed in the
patient flow sheet. Figure 1 explains the relation between
the pathogenesis of VAP and our bundle strategies.
Phase-II started on October 1st 2013 for six months
at which re-evaluation of VAP rate/1000 MV days were
performed to assess the efficacy of our infection control
bundle.
As VAP preventive bundle was part of our Quality
Control Program where internal committee (registered
nurses, infection control physicians) was assigned for
continuous observation of adherence of our unit team
with monthly report about this rate. VAP diagnosis:
VAP was diagnosed by pediatrician and confirmed by at-
tending neonatologist using criteria for less than one year
established by Foglia and colleagues [7]. The criteria
were as follow, neonatal patients who are mechanically
ventilated ≥ 48 h must have new onset and persistent ab-
normal chest radiograph and worsening of gas exchange
(desaturations, increased oxygen requirement or increased
ventilator demand), and at least three of the following:
temperature instability with no other recognized cause;
new onset of purulent sputum, change in character of spu-
tum, increased respiratory secretions, or increased suc-
tioning requirement; apnea, tachypnea, nasal flaring with
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retraction of the chest wall or grunting; wheezing, rales or
rhonchi; cough; and bradycardia (<100 beat/min) or
Tachycardia (>170 beat/min).
Patients
All neonates admitted to NICU during phase-I and II
periods and utilized mechanical ventilation for ≥ 48 h
were eligible. The patient demographic, date of admis-
sion, underlying disease, duration of MV, length of
NICU stay, antibiotics used, and other culture positive
infection while on MV were recorded for each case.
Methods
Complete blood count (CBC), C-reactive protein, blood
culture and non- bronchoscopic broncho-alveolar lavage
(NB-BAL) by passing 6f-8f sterile catheter through the
endotracheal tube and wedging the airway [16] were per-
formed for all clinically suspected VAP. The clinical
microbiological laboratory analyzed the samples using
Bact/Alert 3D- Biomerieux-France and provided micro-
organism identification followed by antibiotic sensitivity
according to the isolate using Vitek MS –Biomerieux-
France. Multidrug resistant organisms need special ABX
sensitivity order.
Ethics
Informed parental consent was obtained to be eligible
for enrollment into the study. The study was done ac-
cording to the rules of the Local Ethics Committee of
Faculty of Medicine, Zagazig University, Egypt. Our in-
stitutional review committee of ethical research ap-
proved the study.
Statistical analysis
Categorical variables were summarized as number and
percent while continuous variables were expressed as
mean ± standard variation. Chi-square test and student
t-test were used for analysis of difference for categorical
and continuous variables respectively. Relative risk ratio,
95 % confidence interval, and p value were determined
for VAP rates outcome. The level of significance was set
at p < 0.05. SPSS statistical software version 16 was used
for data presentation and analysis.
Results
A total of 143 neonates were enrolled in the current
study as 62 cases in phase-I and 81 cases in phase-II.
The two groups were comparable in term of gender,
birth weight, gestational age and mode of delivery as
shown in Table 1.
The leading cause for primary use of mechanical venti-
lation was prematurity and related complication (46/62
cases, 74.2 % versus 63/81, 77.8 % in phase-I and phase
II respectively). Other causes such as perinatal asphyxia
(6/62, 9.7 % versus 11/81, 13.6 %), respiratory causes
other than RDS (4/62, 6.5 % versus 3/81, 3.8 %), con-
genital heart diseases (5/62, 8 % versus 4/88, 4.9 %),
others (1/62, 1.6 % versus 0 %) were diagnosed as pri-
mary causes for mechanical ventilation.
2500 days of mechanical ventilation were accrued dur-
ing the study periods as 1154 MV days in phase-I and
1346 MV days in phase-II. 42/62 (67.74 %) episodes of
VAP were diagnosed during the pre-intervention period
with a rate of 36.4 VAP/1000 MV days. Significant re-
duction in VAP incidence rate was observed after imple-
mentation of our VAP bundle, as 31/81(38.2 %) VAP
events corresponding to 23 VAP/1000 MV days (RR
0.565, 95 % CI 0.408-0.782, Z score 3.437 p = 0.0006)
were diagnosed in phase II as displayed in Table 2.
Concomitant significant reduction in MV days/case
was obvious in the post-intervention period when com-
pared to pre-intervention one (21.50 ± 5.2 days in phase-
I versus 10.36 ± 5.2 days in phase-II, p = 0.000). There
was a trend toward reduction in NICU length of stay
(23.9 ± 10.3 versus 22.8 ± 9.6 days in phase I and phase
II respectively, p = 0.56) but didn’t reach statistical sig-
nificance. 16/62 (25.8 %) mechanically ventilated neo-
nates died in phase-I, 2 cases of them were related to
Fig. 1 Relationship between VAP pathogenesis and its preventive strategies
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VAP caused by multidrug resistant klebsiella pneumo-
niae, compared to 14/81 (17.3 %) in phase-II, one of
them caused by polymicrobial VAP (K. pneumoniae and
Candida). The difference in overall mortality rates be-
tween the two phases didn’t reach statistical significance
(X2 = 1.54, p = 0.215).
73 VAP events were documented throughout the study,
90.4 % (66/73) of them revealed positive isolates on cultur-
ing their NB-BAL (37/42, 88 % in phase-I &29/31, 93.5 %
in phase-II). Gram negative bacteria were the most com-
monly isolated micro-organisms (97.2 % versus 93.1 % in
phase-I and II respectively), klebsiella pneumoniae was the
leading causative pathogen throughout the study period.
No single case of Gram-positive isolates was diagnosed in
phase-I cases, compared to 6.9 % (2 cases) among those in
phase-II. Fungus, namely Candida spp. was the single iso-
late from one case in phase-I, but were isolated mixed
with gram negative bacteria in three cases of phase-II
(10.4 %) as described in Table 3.
Discussion
Advances in neonatal intensive care have improved sur-
vival among very low birth weight infants. As many of
them require mechanical ventilation, VAP become a
major challenge. It represents an important cause of
morbidity and mortality in this high-risk population
[17]. Data obtained from the current study runs in par-
allel with this fact as 50 % (71/134) of mechanically
ventilated neonates enrolled in the study were very low
birth weight (VLBW) and 77 % (111/134) were prema-
ture. Developmental immaturity in the neonatal im-
mune system including greater permeability of the skin
and mucus membrane, lower level of immunoglobulin,
and decreased complement activity increases their sus-
ceptibility to hospital-acquired infection. Mechanical
ventilation and other invasive treatment measures are very
likely to increase risk of oro-pharyngeal or trachea-
bronchial colonization with pathogenic bacteria, VAP




Number of ventilated neonates 62 81
Gender (male)
Number 43 52
% 69.3 64.1 0.52
Gestation age (week)
< 37 Number (%) 45 (72.5) 66 (81.5) 0.21
- 30-37 20 (32.2) 34 (41.9)
- <30 25 (40.3) 32 (39.6)
> 37 Number (%) 17 (27.5) 15 (18.5)
Mean ± SD 32.18 ± 4.5 31.73 ± 4.3 0.57
Birth weight (g)
≤ 2500 Number (%) 48 (77.4) 63 (77.7) 0.99
- < 1500 28 (45) 43 (53)
> 2500 Number (%) 14 (22.6) 18 (22.3)
Mean ± SD 1898 ± 954 1803 ± 1074 0.59
Mode of delivery (% C/S) 32.2 43.2 0.18
Days of mech. ventilation
Min 5 5
Max 51 35
Mean ± SD 21.50 ± 7.6 10.36 ± 5.2 0.000
Length of NICU (day)
Min 7 10
Max 63 45
Mean ± SD 23.87 ± 10.3 22.8 ± 9.7 0.56
Mortality Number (%) 16 (25.8) 14 (17.3) 0.22
SD standard deviation, C/S caesarian section, NICU neonatal intensive care unit
Table 2 Ventilator-associated pneumonia rates
Item Phases
Phase I Phase II
MV Neonate 62 81
VAP episodes 42 31
MV days 1154 1346
VAP % 67.8 38.2
VAP/1000 MV days 36.4 23
Relative Risk (RR) 0.565
95 % C.I. 0.408-0.782
Z score 3.437
P 0.0006
MV mechanical ventilation, VAP ventilator-associated pneumonia, CI
confidence interval
Table 3 Microbiologic features of VAP pathogens
Pathogen Phases Total
Phase I Phase II
Positive Culture (%) 37 (88) 29 (93.5) 66 (90.4)
Gram-negative (%) 36 (97.2) 27 (93.1) 63 (95.5)
- K-pneumoniae 32 (86.5) 23 (79.3) 55 (83.4)
- P-aeruginosa 2 (5.4) 4 (13.8) 6 (9)
- E-coli 2 (5.4) - (-) 2 (3)
Gram-positive (%) - (-) 2 (6.9) 2 (3)
Fungi (%) 1 (2.7) 3a (10.4) 4 (6)
MDR (%) 9 (24.3) 8 (27.6) 17 (25.8)
K klebsiella, P pseudomonas, E Escherichia, MDR multiple-drug resistant, athree
cases in phase-II showed combined K pneumonia and candida spp isolates
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occurs when bacterial, viral or fungal pathogens enter the
sterile lower respiratory tract and lung parenchyma [18].
Several studies have shown a reduction of VAP rate
after guidelines implementation into a bundle [9–15].
The power of the bundle is that it brings together several
evidence-based practices that individually improve care,
but when applied together, may result in an even greater
improvement in the desired outcome [18]. “VAP pre-
ventive bundle” implemented in the present work was
associated with statistically significant reduction in VAP
rates in our NICU (36.4/1000 MV days in phase-1 ver-
sus 23/1000 MV days in phase-II, p = 0.0006). All items
involved in our proposed bundle were derived from con-
trolled trials or health institutes recommendations for
adults, children or neonatal VAP prevention [9–15].
Most adult VAP prevention bundles recommend
elevation of the head of a ventilated patient’s bed from
30-45 degrees to reduce the risk of aspiration of con-
taminated oro-pharyngeal and gastrointestinal content.
Drakulovic and colleagues demonstrated that a semi-
recumbent position reduced the rate of clinically sus-
pected and microbiological confirmed VAP [19]. Only
one underpowered pediatric trial presented in an ab-
stract form has evaluated this intervention and showed
no effect [20]. The logic of head-of-the bed elevation is
sound, it is found in almost every VAP reduction bun-
dle and its implementation was easy and accepted by
health care providers in our work.
There is unequivocal evidence that hand hygiene is the
most important infection control intervention in all
health care setting, but also one of the most difficult
strategy to maintain. Gram negative organisms which
colonize the ETT are frequently carried on the hands of
the care-givers [21, 22]. Several hand hygiene training
campaigns were conducted throughout the study period,
6-steps hand washing posters were displayed on all
sinks, alcohol-based hand rub solution were placed at
each bedside, and in the corridor between rooms to im-
prove compliance with hand hygiene.
Breathing circuit condensate contamination can also
serve as a mechanism for the pathogenesis of VAP, the
condensate that collect in the tubing should be drained
away to prevent aspiration [23]. Center for Disease Con-
trol and Prevention (CDC) recommended; ensuring
proper sterilization of reusable respiratory care equip-
ment, using sterile water in humidification system, peri-
odic drainage of condensate from the breathing circuit
and hand hygiene before and after contact with respiratory
equipment. CDC guidelines do not recommend changing
the breathing circuit unless it is visibly soiled or mechanic-
ally malfunctioning [9]. We followed the CDC strategies
regarding ventilator care in our bundle. Similarly, recent
study concluded that decreasing the ventilator circuit
changes from every 7 days to every 14 days has no adverse
effect on the rate of VAP in NICU [24]. Yuan and his
team reported that the risk factors for the development of
neonatal VAP were re-intubation, frequent ETT suction-
ing, and the duration of mechanical ventilation [25], Tan
and his fellows proved the same findings [26]. The use of
non-invasive measures such as nasal CPAP and nasal
prong ventilation may reduce VAP rate. In time–se-
quenced cohort studies, reducing days of mechanical ven-
tilation by non-invasive respiratory support decreased
VAP incidence [27, 28]. Pneumonia is less common in ne-
onates treated with nasal CPAP when compared with
those intubated on MV (1.9/1000 CPAP days versus 12.5/
1000 MV days, p = 0.04) [27]. Results from the German
Surveillance System for VLBW infants supported the pro-
tected value of NCPAP against pneumonia, as its inci-
dence was 1/1000 CPAP days compared to 2.5/1000 MV
days [29]. In our bundle, attending physician should as-
sess, on daily base, the readiness of every mechanically
ventilated neonate for weaning to NCPAP and every effort
was done to wean them as soon as possible.
Center for Disease Control and Prevention (CDC) rec-
ommended a comprehensive oral hygiene program for
mechanically ventilated patient [9]. A meta- analysis by
Pineda and colleagues showed reduction in VAP among
adult patients treated by decontamination with oral chlor-
hexidine [30]. Similar protective results were concluded
by meta-analysis by Chlebichi and Safdar in which chlor-
hexidine rinse was used [31]. Neonates are likely at greater
risk for aspiration of contaminated oral secretion, because
endotracheal tubes used to ventilate them are un-cuffed
[18]. As chlorhexidine gluconate is not approved for in-
fants less than 2 months, timed mouth care with normal
saline and oro-pharyngeal suction were included in our
bundle.
The criteria defined by Foglia and his colleagues were
used throughout the present study periods to ensure uni-
formity of the results. The CDC/NHSN (National Health
safety Network) proposed protocol clarification in July
2013, at which leukocytosis (>15.000 WBC’s) or leucopenia
(<4000 WBC’s) and shift to left (>10 % band forms) were
added [32]. VAP rates has been reported from both
developed and developing countries, the National
Healthcare Safety Network reported that VAP rate in
level III NICUs of US hospital in 2010 were in the
range 0.4-1.4/1000 MV days [33]. In the International
Nosocomial Infection Control Consortium, the mean
rate from 36 NICUs around the world between January
2004-December 2009 was 9.0/1000 MV days [34]. In
the German Nosocomial Infection Surveillance Sys-
tem, the mean VAP rate was 5.5/1000 MV days [29].
On the other hand, in 55 intensive care units of 8 de-
veloping countries between 2002-2005, the overall VAP
rate was 24.1/1000 MV days ranging from 10.0-52.7/
1000 MV days between units [35]. Data from Asian
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countries suggested an incidence rate varying from 3.5-
46/1000MV days in the newborn period [36]. VAP rate in
our study during the post-intervention period, 23/1000
MV days, was comparable to that in developing countries,
but still significantly higher than the benchmark (1.5/1000
MV days) in developed countries. The lack of respiratory
therapists, overcrowding in hospital, and relatively low
nurse-to-patient ratio in our country’s NICUs may explain
such disparity. In addition, conduct of rigorous hospital-
acquired infection surveillance on a multicenter collabora-
tive network level by NICUs in most developed countries
is a major factor in the gap. Significant reduction in mean
mechanical ventilation days/case were achieved in our ne-
onates in the post-intervention period, an important goal
especially in premature to reduce the hazards of MV in
such population. However, reduction in MV days was not
associated with similar reduction in length of NICU stay,
a finding which is expected when dealing with neonates
particularly premature, as NICU stay is dependent on sev-
eral factors mainly; the baby’s gestational age, severity of
underlying illness and hospital course of which, health-
care associated infection is an important factor.
The overall mortality rate among our cases showed a
trend toward reduction during the post-intervention
period, but didn’t reach statistical significance (17.3 % in
phase-II versus 25.8 % in phase-I, p = 0.215). As we did
not match patient to detect adjusted attributable mortal-
ity, it is not possible to conclude that the reduction in
mortality is attributable to the decrease in VAP rate.
The predominant pathogen of VAP in our study was
bacteria, Gram negative bacteria outnumbered Gram posi-
tive types. Similar finding was shown in Yuan and col-
league work [25] and Xie and team trial [37], while
Staphylococcus aureus and P. aeruginosa were the most
frequently identified pathogen in VAP in western pediatric
populations [38, 39]. The difference in bacterial spectrum
between ours and that reported from western countries
may be due to varied practices, especially antibiotic selec-
tion. Exposure of NICU patients to different antibiotics fa-
vors selection and subsequent colonization with different
pathogens that may leads to VAP. Awareness of local
microbiological surveillance data on hospital-acquired in-
fection can improve the selection of appropriate therapy.
Even-though, the incidence of VAP was reduced with bun-
dle implementation in our NICU, there was no significant
difference in the incidence of multi-drug resistant organ-
isms, probably due to resistant of health care providers to
follow strict antibiotics use as advised by many infection
control specialist [40].
The small sample size was one of our limitations in
this study; we suggest that multicenter approaches may
be necessary to attain larger sample sizes and to evaluate
feasibility/cost-effectiveness. Finally, future longitudinal
cohort studies are recommended to validate the current
findings taking into consideration the rate or level of ad-
herence during the program.
Conclusion
This study provided characterization of VAP in an
Egyptian NICU. It demonstrated that a bundle of infec-
tion control practices can effectively reduce the occur-
rence of VAP during neonatal ventilation. This “VAP
prevention bundle” can be extended to other NICU in
Egypt and other low-income countries.
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